Cynthia X. Ma, MD, PhD, on Benefits of Attendance at AACR

Video

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, following the American Association for Cancer Research Annual Meeting 2021 about the benefits of the meeting to clinical trial investigators.

CancerNetwork® sat down with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, to discuss educational sessions at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Transcript:

I really liked the educational sessions. It’s hard to listen to all the seminars and lectures and but I was able to listen to some of the on-demand sessions. One of those was in targeting DNA-damage repair pathways and immunotherapies, and I thought those were very helpful. I designed trials and see patients [and I] always want to be able to develop trials looking at the most cutting-edge research. We should be able to [do this], we are aiming at [what] translates to the clinic.

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content